Clinical trials: Anticoagulant Drugs
Thrombosis
Vitamin K2 Intervention in Patients With Vitamin K Antagonists
The objective of the SAFE K study is to demonstrate that in patients treated with the antagonists of vitamin K (VKA), a daily intake of vitamin K2 (75 micrograms/day) as naturally produced by the ferments used in fermented dairy…
- Trial name
- SAFEK (NCT01533441)
- Testing
- Vitamin K2
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Danisco
Postpartum Period, Cesarean Section Surgery
Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis Outcomes
Pregnancy and the postpartum period increase venous thromboembolism (VTE) risk. After cesarean section, low-molecular-weight heparin (LMWH; enoxaparin) is commonly used for short-term thromboprophylaxis, but it requires daily…
- Conditions
- Postpartum Period, Cesarean Section Surgery, VTE (Venous Thromboembolism)
- Trial name
- NCT07820670
- Testing
- Rivaroxaban, Enoxaparin 40 mg
- Where
- Israel
- Volunteers
- 62 people
- Sponsor
- Wolfson Medical Center
Venous Thromboembolism, Deep Venous Thrombosis
Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Plastic and reconstructive surgeons consistently create large, raw surfaces as part of their operative procedures. Thus, plastic \& reconstructive surgery patients are among those at highest risk for anticoagulant-associated…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
- Trial name
- NCT03212365
- Testing
- Fixed dose, Variable dose
- Where
- 2 sites in United States
- Volunteers
- 295 people
- Sponsor
- University of Utah
Arthroplasty, Replacement, Hip, Thrombosis
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the…
- Trial name
- NCT00107900
- Testing
- DU-176b
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Daiichi Sankyo
Cardioembolic Stroke, Anticoagulant Therapy
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
This is an observational, prospective, multicenter, cohort study in patients with cardioembolic stroke and previous oral or parenteral anticoagulant therapy.
- Conditions
- Cardioembolic Stroke, Anticoagulant Therapy, Stroke Recurrence, Haemorrhagic Transformation Stroke
- Trial name
- KOALA-IS (NCT05486351)
- Testing
- Observation
- Where
- 3 sites in France, Spain
- Volunteers
- 318 people
- Sponsor
- Instituto de Investigación Hospital Universitario La Paz
Cancer-associated Thrombosis
Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population
The goal of this observational study is to learn about the long-term efficacy and safety of extended anticoagulant treatment in patients with cancer associated thrombosis.
- Trial name
- NCT07388056
- Testing
- Anticoagulant
- Volunteers
- 169 people
- Sponsor
- Thammasat University
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Severe Trauma Patient, Venous Thromboembolism
Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial
Venous thromboembolism is a frequent issue in severe trauma patients. Guidelines for venous thromboembolism prevention include the use of pharmacological thromboprophylaxis, mainly with low-molecular-weight heparin, and/or…
- Trial name
- HEPTRAUMA (NCT07506473)
- Testing
- Enoxaparin standard dose, Enoxaparin intermediate dose
- Where
- 17 sites in France
- Volunteers
- 540 people
- Sponsor
- University Hospital, Grenoble
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- NCT03786757
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
ST Elevation Myocardial Infarction
Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI
This study is aimed to investigate if the bivaliruding with prolonged full dose infusion after PCI is superior to heparin alone in reducing 30-day mortality or major bleeding for patients with STEMI treated with emergency PCI.
- Trial name
- BRIGHT-4 (NCT03822975)
- Testing
- Bivalirudin, unfractionated Heparin
- Where
- 85 sites in China
- Volunteers
- 6,016 people
- Sponsor
- Shenyang Northern Hospital
Hemophilia A
Long-term Anticoagulation in a Patient With Severe Hemophilia A
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII)…
- Trial name
- HAAC (NCT07314983)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- University Hospital, Strasbourg, France
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to examine the superiority of YM150 to the placebo and to evaluate the dose-dependent response of YM150 in patients undergoing elective total knee replacement surgery.
- Trial name
- NCT00917254
- Testing
- YM150, Enoxaparin
- Where
- 13 sites in Japan, Taiwan and 1 more
- Volunteers
- 369 people
- Sponsor
- Astellas Pharma Inc
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine.
- Conditions
- Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- thrombEVAL (NCT01809015)
- Where
- Germany
- Volunteers
- 2,318 people
- Sponsor
- Johannes Gutenberg University Mainz
Deep Vein Thrombosis, Iliac Vein Thrombosis
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
To evaluate the efficacy and safety of combination of anticoagulant and antiplatelet therapy on the patency of iliac vein at 12-month post stenting in patients with acute proximal DVT and ipsilateral iliac vein stenosis who…
- Conditions
- Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction, Iliac Vein Stenosis
- Trial name
- NCT04694248
- Testing
- Rivaroxaban, Aspirin
- Where
- China
- Volunteers
- 172 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Atrial Fibrillation, Medication Adherence
Use of Electronic Personal Health Records to Improve Medication Adherence
The purpose of this pilot study is to examine the use of a personal health record to improve medication adherence among patients with non-valvular atrial fibrillation taking dabigatran for primary prevention of embolic stroke.
- Trial name
- NCT03018197
- Testing
- Medication Education
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Parkview Health
Venous Thromboembolism, Anticoagulant
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal…
- Conditions
- Venous Thromboembolism, Anticoagulant, Elderly
- Trial name
- Jason (NCT04257487)
- Testing
- Sulodexide
- Where
- Italy
- Volunteers
- 1,455 people
- Sponsor
- Arianna Anticoagulazione Foundation
Contrast Agents and Oral Factor Xa Inhibitor
The Effect of Contrast Agents on the Anticoagulant Properties of Oral Factor Xa Inhibitors
The aim of this study is to evaluate the effect of iohexol as a contrast agent on the anticoagulant activity of oral factor Xa inhibitors.
- Trial name
- NCT04611386
- Testing
- computerized tomography
- Where
- Turkey (Türkiye)
- Volunteers
- 65 people
- Sponsor
- Bursa Postgraduate Hospital
Whole Blood Donation and Leukoreduction
Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial
The primary goal of Hemanext. is to improve red cell storage through novel storage methods. Based on our review of the pertinent literature, there is substantial evidence suggesting that prolonged exposure to oxygen during…
- Trial name
- NCT03301779
- Testing
- Hemanext Red Blood Cell Processing System
- Where
- 3 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hemanext
Healthy Volunteers
Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)
The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.
- Trial name
- NCT03578146
- Testing
- PRT064445/Rivaroxaban
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals